UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 30, 2025

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At April 30, 2025, 5,685,365,587 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

33

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

50

Item 4.

Controls and Procedures

50

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

50

Item 1A.

Risk Factors

50

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

50

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information

51

Item 6.

Exhibits

51

Signature

51

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 23, 2025 and February 25, 2024, and for U.S. subsidiaries is as of and for the three months ended March 30, 2025 and March 31, 2024. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2024 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

Indicates calculation not meaningful or results are greater than 100%

2024 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2024

AbbVie

AbbVie Inc.

AI

artificial intelligence

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

Blackstone

Blackstone Life Sciences

BMSBristol-Myers Squibb Company

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

CMS

Centers for Medicare & Medicaid Services

CODMChief Operating Decision Maker

Comirnaty(a)

Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Australia, Eastern Europe, Scandinavian countries, South Korea, New Zealand and Finland

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans), Africa, the Middle East and Turkey

EPS

earnings per share

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended March 30, 2025

GAAPU.S. Generally Accepted Accounting Principles

GSKGSK plc

HaleonHaleon plc

HIPAAHealth Insurance Portability and Accountability Act of 1996

HospiraHospira, Inc.

HRR

homologous recombination repair

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

Medicare Part B

a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare

Medicare Part D

a prescription drug coverage program for people with Medicare

MeridianMeridian Medical Technologies, Inc.

Moody s

Moody s Ratings (formerly Moody s Investors Service)

mRNAmessenger ribonucleic acid

NDA

New Drug Application

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPC

non-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

ODToral disintegrating tablet

Ono

Ono Pharmaceutical Co., Ltd.

OTCover-the-counter

Paxlovid(a)

an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

Pierre Fabre

Pierre Fabre Medicament SAS

Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

R&Dresearch and development

RSVrespiratory syncytial virus

S&PS&P Global (formerly Standard & Poor s)

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

SI&A

Selling, informational and administrative expenses

Takeda

Takeda Pharmaceutical Company Limited

UCulcerative colitis

U.K.United Kingdom

U.S.United States

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

(a)Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)March 30,

2025March 31,

2024

Revenues:

Product revenues

$11,294 $12,443

Alliance revenues

2,113 2,172

Royalty revenues

308 263

Total revenues13,715 14,879

Costs and expenses:

Cost of sales(a)

2,845 3,379

Selling, informational and administrative expenses(a)

3,031 3,495

Research and development expenses(a)

2,203 2,493

Acquired in-process research and development expenses9

Amortization of intangible assets1,211 1,308

Restructuring charges and certain acquisition-related costs678 102

Other (income)/deductions net953 680

Income from continuing operations before provision/(benefit) for taxes on income

2,785 3,421

Provision/(benefit) for taxes on income

(189)293

Income from continuing operations

2,973 3,128

Discontinued operations net of tax (5)

Net income before allocation to noncontrolling interests

2,973 3,123

Less: Net income attributable to noncontrolling interests6 8

Net income attributable to Pfizer Inc. common shareholders

$2,967 $3,115

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

$0.52 $0.55

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.52 $0.55

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

$0.52 $0.55

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

$0.52 $0.55

Weighted-average shares basic5,675 5,657

Weighted-average shares diluted5,710 5,697

(a)Exclusive of amortization of intangible assets.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Net income before allocation to noncontrolling interests$2,973 $3,123

Foreign currency translation adjustments, net(557)140

Unrealized holding gains/(losses) on derivative financial instruments, net(123)217

Reclassification adjustments for (gains)/losses included in net income(a)

(313)(12)

(436)205

Unrealized holding gains/(losses) on available-for-sale securities, net(31)(51)

Reclassification adjustments for (gains)/losses included in net income(b)

155 (14)

124 (65)

Reclassification adjustments related to amortization of prior service costs and other, net(30)(28)

Reclassification adjustments related to curtailments of prior service costs and other, net(33)

(64)(28)

Other comprehensive income/(loss), before tax(932)251

Tax provision/(benefit) on other comprehensive income/(loss)(191)53

Other comprehensive income/(loss) before allocation to noncontrolling interests$(741)$198

Comprehensive income/(loss) before allocation to noncontrolling interests$2,232 $3,321

Less: Comprehensive income/(loss) attributable to noncontrolling interests4 3

Comprehensive income/(loss) attributable to Pfizer Inc.$2,229 $3,319

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)March 30,

2025December 31, 2024

(Unaudited)

Assets

Cash and cash equivalents$1,430 $1,043

Short-term investments15,887 19,434

Trade accounts receivable, net of allowance for doubtful accounts: 2025 $427; 2024 $438

11,845 11,463

Inventories10,852 10,851

Current tax assets2,900 3,314

Other current assets2,947 4,253

Total current assets45,861 50,358

Equity-method investments224 217

Long-term investments1,789 2,010

Property, plant and equipment, net of accumulated depreciation: 2025 $16,842; 2024 $16,483

18,347 18,393

Identifiable intangible assets, net

53,976 55,411

Goodwill68,444 68,527

Noncurrent deferred tax assets and other noncurrent tax assets9,542 8,662

Other noncurrent assets9,845 9,817

Total assets$208,028 $213,396

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2025 $3,749; 2024 $3,747

$4,470 $6,946

Trade accounts payable5,240 5,633

Dividends payable 2,437

Income taxes payable3,105 2,910

Accrued compensation and related items2,607 3,838

Deferred revenues1,012 1,511

Other current liabilities20,016 19,720

Total current liabilities36,452 42,995

Long-term debt57,639 57,405

Pension and postretirement benefit obligations2,021 2,115

Noncurrent deferred tax liabilities2,258 2,122

Other taxes payable5,724 6,112

Other noncurrent liabilities13,297 14,150

Total liabilities117,391 124,899

Commitments and Contingencies

Common stock481 480

Additional paid-in capital93,856 93,603

Treasury stock(115,008)(114,763)

Retained earnings119,590 116,725

Accumulated other comprehensive loss(8,581)(7,842)

Total Pfizer Inc. shareholders equity90,338 88,203

Equity attributable to noncontrolling interests299 294

Total equity90,637 88,497

Total liabilities and equity$208,028 $213,396

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497

Net income

2,967 2,967 6 2,973

Other comprehensive income/(loss), net of tax(738)(738)(3)(741)

Cash dividends declared, per share: $

Common stock

Share-based payment transactions27 1 252 (9)(245)(103)(94)(94)

Other 1 1 2 2

Balance, March 30, 20259,620 $481 $93,856 (3,935)$(115,008)$119,590 $(8,581)$90,338 $299 $90,637

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288

Net income

3,115 3,115 8 3,123

Other comprehensive income/(loss), net of tax203 203 (5)198

Cash dividends declared, per share: $

Common stock

Share-based payment transactions30 1 366 (10)(268)(151)(51)(51)

Other

Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Operating Activities

Net income before allocation to noncontrolling interests$2,973 $3,123

Discontinued operations net of tax (5)

Net income from continuing operations before allocation to noncontrolling interests2,973 3,128

Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization1,618 1,736

Asset write-offs and impairments344 136

Deferred taxes(663)(441)

Share-based compensation expense170 220

Benefit plan contributions in excess of expense/income(229)(201)

Other adjustments, net40 (151)

Other changes in assets and liabilities, net of acquisitions and divestitures(1,919)(3,336)

Net cash provided by/(used in) operating activities2,335 1,090

Investing Activities

Purchases of property, plant and equipment(564)(704)

Purchases of short-term investments(2,823)(797)

Proceeds from redemptions/sales of short-term investments3,955 658

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(3,852)(1,187)

Purchases of long-term investments(134)(35)

Proceeds from redemptions/sales of long-term investments82 305

Proceeds from sales of investment in Haleon(a)

6,311 3,491

Other investing activities, net300

Net cash provided by/(used in) investing activities3,274 1,732

Financing Activities

Proceeds from short-term borrowings 1,444

Payments on short-term borrowings(2,048)(328)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(386)(2,039)

Payments on long-term debt (1,250)

Cash dividends paid(2,437)(2,372)

Other financing activities, net(356)(386)

Net cash provided by/(used in) financing activities(5,227)(4,931)

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(7)(28)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents375 (2,137)

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,107 2,917

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,481 $780

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

$152 $184

Interest paid

353 415

Interest rate hedges74 33

(a) See Note 7A.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2024 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2024 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 23, 2025 and February 25, 2024, and for U.S. subsidiaries is as of and for the three months ended March 30, 2025 and March 31, 2024.

We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.

B. Revenues and Trade Accounts Receivable

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)March 30,

2025December 31, 2024

Reserve against Trade accounts receivable, net of allowance for doubtful accounts

$1,462 $1,627

Other current liabilities:

Accrued rebates8,119 7,195

Other accruals904 972

Other noncurrent liabilities

461 1,029

Total accrued rebates and other sales-related accruals$10,945 $10,822

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three months ended March 30, 2025 and March 31, 2024, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2024 Form 10-K.

Note 2. Research and Development Arrangement

Research and Development Funding Arrangement with Blackstone In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $277 million contingent upon the successful results of the clinical trials and payable to Blackstone over a period of one to three years. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $897 million in total based on achievement of certain levels of cumulative applicable net sales and payable to Blackstone over a period of five

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

to seven years. The net present value of the approval-based milestone payments and sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Accretion of interest on the liabilities to pay Blackstone will be recognized as interest expense in Other (income)/deductions net.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning Our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this initial part of the program to continue primarily through 2025 and to total approximately $3.1 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as non-cash asset write downs of which $2.4 billion is associated with our Biopharma segment.

In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs associated with the additional productivity opportunities to be incurred through 2027 and to total approximately $1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation, of which $700 million is associated with our Biopharma segment.

In connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025 we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in the first quarter of 2025, with cash outlays expected primarily in 2025 and 2026.

We now expect costs associated with all three components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.

From the start of this program through March 30, 2025, we incurred total costs under this program of $3.2 billion, of which $2.7 billion is associated with our Biopharma segment (including $2.5 billion of restructuring charges).

B. Manufacturing Optimization Program

In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $1.6 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through March 30, 2025, we incurred costs under this program of $1.2 billion, substantially all of which is restructuring costs for our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Restructuring charges/(credits):

Employee terminations$384 $(29)

Asset impairments173 25

Exit costs

64 14

Restructuring charges/(credits)(a)

621 10

Transaction costs(b)

Integration costs and other(c)

57 87

Restructuring charges and certain acquisition-related costs678 102

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

(59)3

Additional depreciation asset restructuring recorded in Cost of sales in our condensed consolidated statements of operations(d)

4 4

Implementation costs recorded in our condensed consolidated statements of operations as follows(e):

Cost of sales20 16

Selling, informational and administrative expenses6 29

Research and development expenses24 13

Total implementation costs50 58

Total costs associated with acquisitions and cost-reduction/productivity initiatives$673 $168

(a)In 2025, primarily represents cost-reduction initiatives. In 2024, primarily represented Seagen acquisition-related costs, largely offset by credits for cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program) and credits of $37 million for the three months ended March 31, 2024 for our Realigning our Cost Base Program.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2024(a)

$2,046 $ $74 $2,120

Provision

384 173 64 621

Utilization and other(b)

(249)(173)80 (342)

Balance, March 30, 2025(c)

$2,181 $ $218 $2,399

(a)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($1.8 billion) and Other noncurrent liabilities ($562 million).

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Interest income$(143)$(129)

Interest expense654 790

Net interest expense(a)

511 661

Net (gains)/losses recognized during the period on equity securities(b)

370 (25)

Net periodic benefit costs/(credits) other than service costs(158)(103)

Certain legal matters, net(c)

142 208

Certain asset impairments(d)

224 109

Haleon equity method (income)/loss

88

Other, net(e)

(135)(258)

Other (income)/deductions net$953 $680

(a)The decrease in net interest expense in the first quarter of 2025, compared to the first quarter of 2024, reflects (i) lower interest expense mainly due to lower long-term debt and commercial paper balances and (ii) an increase in interest income primarily due to higher cash balances from sales of our remaining investment in Haleon.

(b)The net losses in the first quarter of 2025 include, among other things, a net loss of $144 million related to our investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment.

(c)The amount for the first quarter of 2025 primarily includes certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.

(d)The amount for the first quarter of 2025 primarily represents an intangible asset impairment charge associated with our Biopharma segment of $210 million for KRAS G12D, a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner. The amount for the first quarter of 2024 represented intangible asset impairment charges associated with our Biopharma segment for developed technology rights due to updated commercial forecasts mainly reflecting competitive pressures.

(e)The first quarter of 2024 primarily included, among other things, a $150 million realized gain on the partial sale of our investment in Haleon.

Additional information about the intangible assets that were impaired during 2025 follows:

Three Months Ended

Fair Value(a)

March 30, 2025

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

Indefinite-lived licensing agreement(b)

$ $ $ $ $210

Developed technology rights(b)

14

Total

$ $ $ $ $224

(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See also Note 1E in our 2024 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Note 5. Tax Matters

A. Taxes on Income/(Loss) from Continuing Operations

Our effective tax rate for continuing operations was (6.8)% for the first quarter of 2025, compared to 8.6% for the first quarter of 2024. The negative and lower effective tax rate for the first quarter of 2025, compared to the first quarter of 2024, was primarily due to favorable global income tax resolutions in multiple tax jurisdictions spanning multiple tax years, as well as a favorable change in the jurisdictional mix of earnings.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The seventh annual installment was paid by its April 15, 2025 due date and is reported in current Income taxes payable as of March 30, 2025. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.

See Note 5A in our 2024 Form 10-K for information on our cash paid for income taxes, net of refunds.

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019 - 2022 are under audit. The IRS audit of Pfizer s federal income tax returns for years 2016-2018 is effectively settled but the statute of limitation remains open for these tax years. Tax years 2023-2025 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2014.

See Note 5D in our 2024 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Foreign currency translation adjustments, net(a)

$(102)$25

Unrealized holding gains/(losses) on derivative financial instruments, net(34)45

Reclassification adjustments for (gains)/losses included in net income

(55)(4)

(89)41

Unrealized holding gains/(losses) on available-for-sale securities, net(4)(6)

Reclassification adjustments for (gains)/losses included in net income

19 (2)

15 (8)

Reclassification adjustments related to amortization of prior service costs and other, net(7)(5)

Reclassification adjustments related to curtailments of prior service costs and other, net(9)

(16)(5)

Tax provision/(benefit) on other comprehensive income/(loss)$(191)$53

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, January 1, 2025

$(7,984)$57 $(106)$191 $(7,842)

Other comprehensive income/(loss)(b)

(453)(347)109 (48)(738)

Balance, March 30, 2025$(8,436)$(290)$3 $143 $(8,581)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

March 30, 2025December 31, 2024

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Equity securities with readily determinable fair value(a)

$1,255 $ $1,255 $7,848 $6,456 $1,392

Available-for-sale debt securities:

Government and agency non-U.S.

8,995 8,995 6,855 6,855

Government and agency U.S.

3,494 3,494 2,853 2,853

Corporate and other

1,464 1,464 1,173 1,173

13,952 13,952 10,881 10,881

Total short-term investments15,207 15,207 18,729 6,456 12,273

Other current assets

Derivative assets:

Interest rate contracts

2 2

Foreign exchange contracts

548 548 1,056 1,056

Total other current assets550 550 1,056 1,056

Long-term investments

Equity securities with readily determinable fair values(b)

1,031 1,031 1,246 1,246

Total long-term investments1,031 1,031 1,246 1,246

Other noncurrent assets

Derivative assets:

Interest rate contracts

36 36 13 13

Foreign exchange contracts

256 256 447 447

Total derivative assets292 292 460 460

Insurance contracts(c)

849 849 875 875

Total other noncurrent assets1,141 1,141 1,335 1,335

Total assets$17,929 $1,031 $16,899 $22,366 $7,701 $14,665

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$10 $ $10 $28 $ $28

Foreign exchange contracts

200 200 217 217

Total other current liabilities210 210 245 245

Other noncurrent liabilities

Derivative liabilities:

Interest rate contracts278 278 397 397

Foreign exchange contracts

826 826 723 723

Total other noncurrent liabilities1,104 1,104 1,121 1,121

Total liabilities$1,314 $ $1,314 $1,366 $ $1,366

(a)Includes money market funds primarily invested in U.S. Treasury and government debt. As of December 31, 2024, short-term equity securities included our investment in Haleon of $6.5 billion. In the first quarter of 2025, we sold the remaining portion of our investment in Haleon for $6.3 billion.

(b)Long-term equity securities of $132 million as of March 30, 2025 and $133 million as of December 31, 2024 were held in restricted trusts for U.S. non-qualified employee benefit plans.

(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $58 billion as of March 30, 2025 and $57 billion as of December 31, 2024. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $55 billion as of March 30, 2025 and $54 billion as of December 31, 2024.

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 30, 2025 and December 31, 2024. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Investments

Total Short-Term, Long-Term and Equity-Method Investments

The following summarizes our investments by classification type:

(MILLIONS)March 30,

2025 December 31, 2024

Short-term investments

Equity securities with readily determinable fair values

$1,255 $7,848

Available-for-sale debt securities13,952 10,881

Held-to-maturity debt securities679 705

Total Short-term investments$15,887 $19,434

Long-term investments

Equity securities with readily determinable fair values(a)

$1,031 $1,246

Held-to-maturity debt securities47 45

Private equity securities at cost(a)

712 719

Total Long-term investments$1,789 $2,010

Equity-method investments224 217

Total long-term investments and equity-method investments$2,014 $2,228

Held-to-maturity cash equivalents$262 $184

(a)Represent investments in the life sciences sector.

Debt Securities

Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:

March 30, 2025December 31, 2024

Gross Unrealized Maturities (in Years)

Gross Unrealized

(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1

to 5Over 5Amortized CostGainsLossesFair Value

Available-for-sale debt securities

Government and agency non-U.S.

$8,986 $39 $(31)$8,995 $8,995 $ $ $6,970 $8 $(123)$6,855

Government and agency U.S.

3,494 3,494 3,494 2,853 2,853

Corporate and other1,469 (5)1,464 1,464 1,179 (6)1,173

Held-to-maturity debt securities

Time deposits and other

739 739 696 22 20 697 697

Government and agency non-U.S.

249 249 245 4 1 237 237

Total debt securities$14,937 $39 $(36)$14,941 $14,894 $26 $21 $11,935 $8 $(129)$11,814

Any expected credit losses to these portfolios would be immaterial to our financial statements.

Equity Securities

The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024

Net (gains)/losses recognized during the period on equity securities(a)

$370 $(25)

Less: Net (gains)/losses recognized during the period on equity securities sold during the period(924)(214)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)

$1,295 $188

(a)Reported in Other (income)/deductions net. See Note 4.

(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of March 30, 2025, there were cumulative impairments and downward adjustments of $400 million and upward adjustments of $223 million. Impairments, downward and upward adjustments were not material to our operations in the first quarters of 2025 and 2024.

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Short-Term Borrowings

Short-term borrowings include:

(MILLIONS)March 30,

2025 December 31, 2024

Commercial paper, principal amount

$155 $2,453

Current portion of long-term debt, principal amount3,750 3,750

Other short-term borrowings, principal amount(a)

567 755

Total short-term borrowings, principal amount

4,471 6,957

Net unamortized discounts, premiums and debt issuance costs(1)(12)

Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted

$4,470 $6,946

(a)Primarily includes cash collateral. See Note 7F.

D. Long-Term Debt

The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:

(MILLIONS)March 30,

2025 December 31, 2024

Total long-term debt, principal amount$57,257 $57,147

Net fair value adjustments related to hedging and purchase accounting820 701

Net unamortized discounts, premiums and debt issuance costs(437)(444)

Total long-term debt, carried at historical proceeds, as adjusted$57,639 $57,405

E. Derivative Financial Instruments and Hedging Activities

Foreign Exchange Risk A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.

The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Chinese renminbi, Canadian dollar and Swedish krona, and include a portion of our forecasted foreign exchange-denominated intercompany inventory sales hedged up to two years. We may also seek to protect against possible declines in the net investments of our foreign business entities.

Interest Rate Risk Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.

The following summarizes the fair value of the derivative financial instruments and notional amounts:

March 30, 2025December 31, 2024

Fair ValueFair Value

(MILLIONS)NotionalAssetLiabilityNotionalAssetLiability

Derivatives designated as hedging instruments:

Foreign exchange contracts(a)

$24,291 $680 $869 $23,991 $1,250 $719

Interest rate contracts6,750 37 287 6,750 13 425

718 1,156 1,263 1,144

Derivatives not designated as hedging instruments:

Foreign exchange contracts$18,889 124 157 $26,335 253 221

Total$842 $1,314 $1,516 $1,366

(a)The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.9 billion as of March 30, 2025 and $5.0 billion as of December 31, 2024.

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures:

Gains/(Losses)

Recognized in OID(a)

Gains/(Losses)

Recognized in OCI(a)

Gains/(Losses)

Reclassified from

OCI into OID and COS(a)

Three Months Ended

(MILLIONS)March 30,

2025March 31,

2024March 30,

2025March 31,

2024March 30,

2025March 31,

2024

Derivative Financial Instruments in Cash Flow Hedge Relationships:

Interest rate contracts

$ $ $ $ $2 $

Foreign exchange contracts(b)

(138)210 295 4

Amount excluded from effectiveness testing and amortized into earnings(c)

15 7 16 7

Derivative Financial Instruments in Fair Value Hedge Relationships:

Interest rate contracts

142 (188)

Hedged item

(142)188

Derivative Financial Instruments in Net Investment Hedge Relationships:

Foreign exchange contracts

(437)235

Amount excluded from effectiveness testing and amortized into earnings(c)

75 21 41 37

Non-Derivative Financial Instruments in Net Investment Hedge Relationships(d):

Foreign currency long-term debt (31)18

Derivative Financial Instruments Not Designated as Hedges:

Foreign exchange contracts

(31)55

$(31)$55 $(517)$490 $354 $49

(a)OID = Other (income)/deductions net, included in Other (income)/deductions net in the condensed consolidated statements of operations. COS = Cost of Sales, included in Cost of sales in the condensed consolidated statements of operations. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income/(loss).

(b)The amounts reclassified from OCI into COS were a net gain of $62 million in the first quarter of 2025 and a net gain of $31 million in the first quarter of 2024. The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $94 million within the next 12 months into income. The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 18 years and relates to foreign currency debt.

(c)The amounts reclassified from OCI were reclassified into OID.

(d)Long-term debt includes foreign currency borrowings, which are used in net investment hedges; the related carrying values as of March 30, 2025 and December 31, 2024 were $808 million and $777 million, respectively.